AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02455804 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stenting procedure
Description: All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
Study NCT04661111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hymovis® ONE (32 mg/4 ml)
Description: Hymovis® ONE is a clear hydrogel. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process. Hymovis® ONE is a CE-marked Class III Medical Device intended for intra-articular injection.
Study NCT01057693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
Study NCT01057693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as capsules and given 3 times daily.
Study NCT02413996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinetec® knee continuous passive motion (CPM )
Description: CPM of the knee
Study NCT02413996 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinetec® knee continuous passive motion (CPM )
Description: CPM of the knee
Study NCT02413996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional activities
Description: Stairs, walking
Study NCT02413996 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional activities
Description: Stairs, walking
Study NCT02413996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRRS rehabilitation
Description: exercise therapy through a virtual reality rehabilitation system (VRRS)
Study NCT02413996 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation
Description: exercise therapy through a traditional rehabilitation training made by physiotherapists
Study NCT00126191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle
Study NCT01148472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 20mg once daily; orally
Study NCT01972724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone tablets
Study NCT01972724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin as prescribed in clinical practice
Study NCT01972724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea as prescribed in clinical practice
Study NCT00640146 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to methylnaltrexone will be administered as per the dose and schedule specified in the respective arm.
Study NCT01485432 — intervention group
Intervention type: DEVICE
Intervention: PiCCO® Monitoring
Description: Fluid and vasopressor management according to PiCCO measurements
Study NCT02046382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: 1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
Study NCT02046382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
Study NCT02966613 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GMK Medacta Total Knee arthroplasty
Description: Total Knee arthroplasty
Study NCT02966613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GMK Medacta Total Knee arthroplasty
Description: Total Knee arthroplasty
Study NCT02564744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 1562
Description: Administered as IV Infusion.
Study NCT00712933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belimumab
Description: Recombinant, fully human, monoclonal antibody~Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days.
Study NCT01280019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar recruitment manoeuvre
Description: Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.
Study NCT01280019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar recruitment manoeuvre
Description: Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.
Study NCT01808404 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-Based Guided Self-Help
Description: The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based lessons in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness.
Study NCT01736423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM060
Description: oral
Study NCT02526212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: G-BMT
Description: The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
Study NCT01148472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: 60mg once daily; orally
Study NCT02469298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1325756 (Danirixin)
Description: It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use
Study NCT02469298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo To Match GSK1325756
Description: It will be supplied as capsule shaped white film coated placebo tablet for oral use
Study NCT02469298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo To Match GSK1325756
Description: It will be supplied as capsule shaped white film coated placebo tablet for oral use
Study NCT02469298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir Phosphate
Description: It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
Study NCT02469298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Phosphate
Description: It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
Study NCT04443842 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial and social incentives
Description: Participants will be credited with HK$1000 in their virtual accounts at the beginning of the trial. After baseline step counts are gathered in the second week, participants will lose HK$40 for each subsequent week that they do not meet their personal weekly step target.~The social incentives are peer comparison and social support. Participants receive feedback of their physical activity performance by assessing whether they met or exceeded their step count target, followed by positive messages for encouragement. Nominated supporters will be informed of participants' performance for social support.
Study NCT02469298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo To Match Oseltamivir Phosphate
Description: It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
Study NCT02469298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo To Match Oseltamivir Phosphate
Description: It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
Study NCT00814307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 5mg CP-690,550 BID PO for 6 months
Study NCT00814307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: 10 mg CP-690,550 BID PO for 6 months
Study NCT00814307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
Study NCT00814307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
Study NCT02526212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
Study NCT02526212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: All participants will continue to receive maintenance treatment with buprenorphine-naloxone
Study NCT02526212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: All participants will continue to receive maintenance treatment with buprenorphine-naloxone
Study NCT04741321 — intervention group
Intervention type: OTHER
Intervention: VascuQol-6 questionnaire Spanish version
Description: VascuQol-6 questionnaire was translated by two professional translators into Spanish.
Study NCT03338478 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Wii Balance Board
Description: Participants will stand on the Wii Balance Board with eyes open, eyes closed, one two feet, and then standing on one leg at each study visit.
Study NCT05802511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate treatment
Description: Exablate treatment for Neuropathic Pain
Study NCT00646113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™ TX 3.0S
Description: OsseoSpeed™ TX 3.0 mm diameter
Study NCT03182621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THINK
Description: The THINK curriculum was based on the principles of exercise physiology and health behaviors. Sessions included educational components, concentrating on physiology, nutrition, laboratory experiences, and structured physical fitness activities.
Study NCT01390298 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational study only
Study NCT00517816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1671
Description: Administered iv at escalating doses (with a starting dose of 0.0015mg)
Study NCT03182621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPARK
Description: traditional YMCA program
Study NCT00004467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: Infusion of 5% dextrose with N-acetylcysteine with an initial loading dose of 150 mg/kg/h of NAC over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusions of 6.25 mg/kg/h for the remaining 67 hours.
Study NCT00004467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion of 5% dextrose
Study NCT04916756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 MG
Description: baricitinib 2mg per day for 24 weeks
Study NCT02024945 — intervention group
Intervention type: DRUG
Intervention: Propiverine
Description: Propiverine 15 mg tablets or 30 mg regulated release capsules
Study NCT00642967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy Polyethylene Glycol-epoetin Beta
Description: Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks for a total of 48 weeks in this single-arm study. The first dose of 120 or 200 mcg will be determined based on the previous dose of epoetin or darbepoetin received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
Study NCT04493463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg + Ropivacaine + Saline
Description: To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the treatment group will consist of a total of 30 ml study solution, containing 1 ml of 40 mg methylprednisolone plus 15ml of 1% ropivacaine and 14 ml saline.
Study NCT04493463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine + Saline
Description: To infiltrate the study solution, the surgeon will inject the incision site with a 10 cm long, 22-gauge needle before the closing of the incision site. A standard volume of 10 ml in each level will be injected, based on the study by Milligan et al., with a total of 5ml study solution injected laterally into the erector spinae muscle and 5 ml subcutaneously along both margins of the incision. This standardization will be on the basis of the number of levels to be treated, and will be consistent in each patient. The depth of penetration will include the subcutaneous tissues, paravertebral muscles, along with the deep muscles surrounding the spinous process, lamina, transverse process and facet joints; the epidural space and intrathecal space will be spared. The local infiltration solution in the control group will consist of a total of 30 ml study solution, containing 15 ml of 1% ropivacaine and 15ml saline.
Study NCT02650895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efprezimod alfa
Description: Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
Study NCT02650895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% sodium chloride
Study NCT04425460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
Study NCT04425460 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo combined with supportive care recommended in the current National/Local guidelines. Placebo dosage and method of administration: Day 1 1800 mg x2; Day 2 up to a maximum of 14 days 600 mg x 3
Study NCT00810589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levemir
Description: 0,4 IE per kg bodyweight
Study NCT00810589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog NPL Insulin
Description: 0,4 IE per kg bodyweight
Study NCT01502358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent Dengue Vaccine (TVDV)
Description: Low dose delivered intramuscularly on Study Days 0, 30 and 90
Study NCT01502358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)
Description: Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
Study NCT01502358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)
Description: High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
Study NCT03765710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recommended protein intake
Description: Recommended protein intake in a mixed meal contained 13% protein, 54% carbohydrate, and 33% fat.
Study NCT03765710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elevated protein intake
Description: Increased protein intake in a mixed meal contained 26% protein, 44% carbohydrate, and 30% fat.
Study NCT00136838 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral or active cigarette cues
Description: Packets of cigarettes or cigarette smoke.
Study NCT00040742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ginger
Description: Given orally
Study NCT00040742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study NCT00040742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT03712176 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lifestyle alteration
Description: Patients will receive self-report questionnaires to evaluate their quality of life, fatigue level, anxiety and depression, cognitive complaint, cognitive efficiency, nutritional quality and food preferences, and sedentary behavior. Patients will also do tests to determine their physical conditions : six-minute walk test (6MWT), 30-s chair-stand test. The intervention will be done at three stages of the patient's care pathway: 1 / before the adjuvant surgery (baseline), 2 / at 6 months after the surgery and chemotherapy 3 / at 7 months after radiotherapy treatment.
Study NCT02370823 — intervention group
Intervention type: PROCEDURE
Intervention: Regenexx SD
Description: stem cell treatment
Study NCT02350335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine (transdermal)
Description: Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
Study NCT02531139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAP maintained at 80 mmHg
Description: Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.
Study NCT02531139 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MAP maintained at 60 mmHg
Description: Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
Study NCT02011230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hoist Group
Description: Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
Study NCT00955643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen
Study NCT00955643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: other
Study NCT03748706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTI-125, 100 mg tablets
Description: PTI-125, 100 mg tablets taken twice a day for 28 days
Study NCT01632852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL362
Description: CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.~CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362.
Study NCT04340388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir 50 MG
Description: 15 participants will be randomized to remain on fully suppressive background antiretroviral therapy. The third agent will be switched to dolutegravir at the dose of 50 mg daily.
Study NCT04340388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiretroviral/Anti HIV
Description: 15 participants with suppressed HIV disease for greater than or equal to 3 months will be randomized to remain on their current 2 or 3 drug fully suppressive antiretroviral regimen.
Study NCT00930917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyethylene cap
Description: In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
Study NCT00930917 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene wrap
Description: Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
Study NCT00930917 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.